Movatterモバイル変換


[0]ホーム

URL:


SG11201809700YA - Gdf15 fusion proteins and uses thereof - Google Patents

Gdf15 fusion proteins and uses thereof

Info

Publication number
SG11201809700YA
SG11201809700YASG11201809700YASG11201809700YASG11201809700YASG 11201809700Y ASG11201809700Y ASG 11201809700YASG 11201809700Y ASG11201809700Y ASG 11201809700YASG 11201809700Y ASG11201809700Y ASG 11201809700YASG 11201809700Y ASG11201809700Y ASG 11201809700YA
Authority
SG
Singapore
Prior art keywords
pennsylvania
international
fusion proteins
road
rule
Prior art date
Application number
SG11201809700YA
Inventor
Anthony Armstrong
Judith Ann Connor
Jennifer Furman
Chichi Huang
Michael J Hunger
Xiefan Lin-Schmidt
Serena Nelson
Shamina Rangwala
Shannon Mullican
Jose Antonio Chavez
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech IncfiledCriticalJanssen Biotech Inc
Publication of SG11201809700YApublicationCriticalpatent/SG11201809700YA/en

Links

Classifications

Landscapes

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111111111111111111111111111111111111111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/196647 Al 16 November 2017 (16.11.2017) WIPO I PCT (51) International Patent Classification: San Diego, California 92121 (US). HUANG, Chichi; 1400 A61K 9/00 (2006.01) CO 7K 14/00 (2006.01) McKean Road, Spring House, Pennsylvania 19477 (US). A61K 38/00 (2006.01) C07K 14/495 (2006.01) HUNGER, Michael J.; 3210 Merryfield Row, San Diego, A61K 38/18 (2006.01) C07K 14/765 (2006.01) California 92121 (US). LIN-SCHMIDT, Xiefan; 1400 (21) International Application Number: McKean Road, Spring House, Pennsylvania 19477 (US). NELSON, Serena; 3210 Merryfield Row, San Diego, Cal- PCT/US2017/031197 ifornia 92121 (US). RANGWALA, Shamina; 1400 McK- (22) International Filing Date: can Road, Spring House, Pennsylvania 19477 (US). MUL- 05 May 2017 (05.05.2017) LICAN, Shannon; 1400 McKean Road, Spring House, (25) Filing Language: English Pennsylvania 19477 (US). CHAVEZ, Jose Antonio; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). (26) Publication Language: English (81) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of national protection available): AE, AG, AL, AM, 62/333,886 10 May 2016 (10.05.2016) US AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (71) Applicant: JANSSEN BIOTECH, INC. [US/US]; DZ, EC, EE, EG, ES, FL GB, GD, GE, GH, GM, GT, HN, 800/850 Ridgeview Drive, Horsham, Pennsylvania 19044 HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, (US). KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, — (72) Inventors: ARMSTRONG, Anthony; 1400 McKean MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, Road, Spring House, Pennsylvania 19477 (US). CONNOR, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, Judith Ann; 3210 Merryfield Row, San Diego, California SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 92121 (US). FURMAN, Jennifer; 3210 Merryfield Row, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = Title: GDF15 FUSION PROTEINS AND USES THEREOF (54) = Figure 1A = = = = = ‘s = gin AV - _ GDF15 = = = = _ _ = _ Il Ir ... ' 71' TG933 0\ 1-1 ---- (57) : Fusion proteins containing a half-life extension protein, a linker, and a GDF15 protein are described. Also described IN ,—I are nucleic acids encoding the fusion proteins, recombinant cells thereof, compositions comprising the fusion proteins, and methods of 0 using the fusion proteins for treating or preventing metabolic diseases, disorders or conditions. ei C [Continued on next page] WO 2017/196647 Al MIDEDIMOMOIDEIROIDEMOMOHEIRIEHOEUVOIMIE (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a))
SG11201809700YA2016-05-102017-05-05Gdf15 fusion proteins and uses thereofSG11201809700YA (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US201662333886P2016-05-102016-05-10
PCT/US2017/031197WO2017196647A1 (en)2016-05-102017-05-05Gdf15 fusion proteins and uses thereof

Publications (1)

Publication NumberPublication Date
SG11201809700YAtrue SG11201809700YA (en)2018-11-29

Family

ID=60266761

Family Applications (2)

Application NumberTitlePriority DateFiling Date
SG10201912739XASG10201912739XA (en)2016-05-102017-05-05Gdf15 fusion proteins and uses thereof
SG11201809700YASG11201809700YA (en)2016-05-102017-05-05Gdf15 fusion proteins and uses thereof

Family Applications Before (1)

Application NumberTitlePriority DateFiling Date
SG10201912739XASG10201912739XA (en)2016-05-102017-05-05Gdf15 fusion proteins and uses thereof

Country Status (28)

CountryLink
US (3)US10336812B2 (en)
EP (1)EP3454832A4 (en)
JP (3)JP7022879B2 (en)
KR (2)KR20230169417A (en)
CN (1)CN109451726A (en)
AR (1)AR108442A1 (en)
AU (3)AU2017263237B2 (en)
BR (1)BR112018072946A2 (en)
CA (1)CA3022865A1 (en)
CL (1)CL2018003148A1 (en)
CO (1)CO2018012096A2 (en)
CR (2)CR20230026A (en)
DO (1)DOP2018000245A (en)
EA (1)EA201892561A1 (en)
EC (1)ECSP18083561A (en)
IL (3)IL302720B2 (en)
MA (1)MA44986A (en)
MX (2)MX2018013784A (en)
MY (1)MY191030A (en)
NI (1)NI201800121A (en)
PE (2)PE20190352A1 (en)
PH (1)PH12018502361B1 (en)
SG (2)SG10201912739XA (en)
SV (1)SV2018005781A (en)
TW (3)TWI760333B (en)
UA (1)UA129532C2 (en)
WO (1)WO2017196647A1 (en)
ZA (1)ZA201808284B (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CN103533951B (en)2011-04-082017-04-19安姆根有限公司Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
KR102376451B1 (en)2013-07-312022-03-23암젠 인크Growth differentiation factor 15 (gdf-15) constructs
EP3184106A1 (en)*2015-12-232017-06-28Sanofi-Aventis Deutschland GmbHGrowth differentiation factor 15 as biomarker for metformin
US10336812B2 (en)*2016-05-102019-07-02Janssen Biotech, Inc.GDF15 fusion proteins and uses thereof
US20190248852A1 (en)2016-05-242019-08-15Novo Nordisk A/SMIC-1 Compounds and Use Thereof
US20190224278A1 (en)*2018-01-222019-07-25Intelligent Synthetic Biology CenterProducing method of antimicrobial peptide with enhanced adhesion and uses thereof
US12398209B2 (en)2018-01-222025-08-26Janssen Biotech, Inc.Methods of treating cancers with antagonistic anti-PD-1 antibodies
TWI724392B (en)2018-04-062021-04-11美商美國禮來大藥廠Growth differentiation factor 15 agonist compounds and methods of using the same
EP3773656A1 (en)2018-04-092021-02-17Amgen Inc.Growth differentiation factor 15 fusion proteins
US11713345B2 (en)2018-10-222023-08-01Janssen Sciences Ireland Unlimited CompanyGlucagon like peptide 1 (GLP1)-growth differentiation factor 15 (GDF15) fusion proteins and uses thereof
EP3870215A1 (en)*2018-10-262021-09-01Vrije Universiteit BrusselNew tools for improving gene therapy and use thereof
JOP20210111A1 (en)*2018-11-202023-01-30Janssen Pharmaceutica NvGdf15 analogs and methods for use in decreasing body weight and/or reducing food intake
WO2020175931A1 (en)*2019-02-272020-09-03주식회사 대웅제약Composition comprising albumin-coupled slit3 lrrd2 for prevention or treatment of muscle disease
EP3932430A4 (en)*2019-02-272023-02-01Daewoong Pharmaceutical Co., Ltd.Albumin-bound composition including lrrd2 of slit3 protein for prevention or treatment of bone-related diseases
MX2021012964A (en)*2019-04-232021-12-10Lg Chemical LtdFusion polypeptide comprising fc region of immunoglobulin and gdf15.
US20230210950A1 (en)*2019-10-042023-07-06Amgen Inc.Use of gdf15 for treating cardiometabolic syndrome and other conditions
CN112618698B (en)*2019-10-082021-10-08北京东方百泰生物科技股份有限公司Injection preparation of human interleukin 10-Fc fusion protein
US20230002460A1 (en)*2019-11-262023-01-05Yuhan CorporationLong-acting gdf15 fusion protein and pharmaceutical composition comprising same
WO2021118256A1 (en)*2019-12-112021-06-17주식회사 엘지화학Fusion polypeptide comprising gdf15 and polypeptide region capable of o-glycosylation
CN115260313B (en)2019-12-312023-07-18北京质肽生物医药科技有限公司 Fusion proteins of GLP-1 and GDF15 and conjugates thereof
CN111393526B (en)*2020-03-302022-04-12中国人民解放军第四军医大学anti-GDF 15 neutralizing monoclonal antibody and application thereof
EP4237438A4 (en)*2020-10-272024-11-27Beijing QL Biopharmaceutical Co., Ltd. FUSION PROTEINS OF GDF15 AND USE THEREOF
WO2023025129A1 (en)*2021-08-242023-03-02广东东阳光药业有限公司Gdf15 fusion protein and use thereof
WO2023154953A1 (en)2022-02-142023-08-17Ngm Biopharmaceuticals, Inc.Gdf15 polypeptides for treating and preventing autoimmune diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
AU8591198A (en)1997-07-311999-02-22Johns Hopkins University School Of Medicine, TheGrowth differentiation factor-15
US7919084B2 (en)*2002-06-172011-04-05St. Vincent's Hospital Sydney LimitedMethods of diagnosis, prognosis and treatment of cardiovascular disease
AU2004251145C1 (en)*2003-06-122011-04-14Eli Lilly And CompanyGLP-1 analog fusion proteins
US20090099031A1 (en)*2005-09-272009-04-16Stemmer Willem PGenetic package and uses thereof
WO2010048670A1 (en)*2008-10-312010-05-06St Vincent's Hospital Sydney LimitedMethod of prognosis in chronic kidney disease
TW201101990A (en)2009-07-082011-01-16zhen-zheng HuangPlant media
NZ597580A (en)*2009-07-202013-11-29Univ Nat TaiwanPolypeptides selective for alpha.v.beta.3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof
EA201491413A1 (en)2012-01-262015-03-31Эмджен Инк. POLYPEPTIDE GROWTH FACTOR AND DIFFERENTIATION 15 (GDF-15)
JP6254146B2 (en)2012-03-272017-12-27エヌジーエム バイオファーマシューティカルス,インコーポレーテッド Compositions and methods for treating metabolic disorders
US9695228B2 (en)*2012-11-212017-07-04Janssen Biotech, Inc.EGFR and c-Met fibronectin type III domain binding molecules
CN105073133B (en)*2012-12-212021-04-20Aveo制药公司 Anti-GDF15 antibody
WO2014116937A1 (en)*2013-01-252014-07-31Janssen Biotech, Inc.Kv1.3 antagonists and methods of use
CA2899170C (en)2013-01-302022-08-02Ngm Biopharmaceuticals, Inc.Compositions and methods of use in treating metabolic disorders
US9161966B2 (en)*2013-01-302015-10-20Ngm Biopharmaceuticals, Inc.GDF15 mutein polypeptides
KR102376451B1 (en)2013-07-312022-03-23암젠 인크Growth differentiation factor 15 (gdf-15) constructs
US20170204149A1 (en)*2014-06-232017-07-20Novartis AgHsa-gdf-15 fusion polypeptide and use thereof
US9272019B2 (en)*2014-06-242016-03-01Novo Nordisk A/SMIC-1 fusion proteins and uses thereof
MX370115B (en)2014-07-302019-12-02Ngm Biopharmaceuticals IncCompositions and methods of use for treating metabolic disorders.
JP6663428B2 (en)*2014-10-302020-03-11アクセルロン ファーマ, インコーポレイテッド Methods and compositions for increasing red blood cells using a GDF15 polypeptide
GB201512733D0 (en)*2015-07-202015-08-26Genagon Therapeutics AbTherapeutic agents for treating conditions associated with elevated GDF15
US10336812B2 (en)*2016-05-102019-07-02Janssen Biotech, Inc.GDF15 fusion proteins and uses thereof
MA46523A (en)*2016-10-122019-08-21Janssen Biotech Inc PROCESSES FOR SCREENING MODULATORS OF A GDF15 TYPE BIOLOGICAL ACTIVITY
US11713345B2 (en)*2018-10-222023-08-01Janssen Sciences Ireland Unlimited CompanyGlucagon like peptide 1 (GLP1)-growth differentiation factor 15 (GDF15) fusion proteins and uses thereof

Also Published As

Publication numberPublication date
TWI853223B (en)2024-08-21
SG10201912739XA (en)2020-02-27
JP2019523637A (en)2019-08-29
US10336812B2 (en)2019-07-02
TW202225183A (en)2022-07-01
AU2021218103B2 (en)2023-08-17
PH12018502361A1 (en)2019-09-23
CN109451726A (en)2019-03-08
KR102818007B1 (en)2025-06-12
EA201892561A1 (en)2019-04-30
UA129532C2 (en)2025-05-28
MA44986A (en)2019-03-20
US20230119382A1 (en)2023-04-20
BR112018072946A2 (en)2019-02-19
MX2024002398A (en)2024-04-03
PE20240015A1 (en)2024-01-04
IL302720B1 (en)2025-03-01
IL302720B2 (en)2025-07-01
CL2018003148A1 (en)2018-12-28
TW201803892A (en)2018-02-01
IL262652A (en)2018-12-31
CO2018012096A2 (en)2018-11-22
TW202446785A (en)2024-12-01
AR108442A1 (en)2018-08-22
MX2018013784A (en)2019-03-28
AU2021218103A1 (en)2021-09-09
JP2024102147A (en)2024-07-30
EP3454832A4 (en)2019-12-18
DOP2018000245A (en)2019-07-15
CA3022865A1 (en)2017-11-16
PH12018502361B1 (en)2024-03-27
SV2018005781A (en)2019-03-28
EP3454832A1 (en)2019-03-20
ZA201808284B (en)2021-10-27
NI201800121A (en)2019-02-18
AU2023266233A1 (en)2023-12-07
TWI760333B (en)2022-04-11
JP7022879B2 (en)2022-02-21
CR20230026A (en)2023-03-13
AU2017263237B2 (en)2021-05-20
KR20190003746A (en)2019-01-09
WO2017196647A1 (en)2017-11-16
JP7481319B2 (en)2024-05-10
ECSP18083561A (en)2018-11-30
IL262652B1 (en)2023-06-01
PE20190352A1 (en)2019-03-07
IL302720A (en)2023-07-01
US20190292241A1 (en)2019-09-26
US11208464B2 (en)2021-12-28
US20170327560A1 (en)2017-11-16
AU2017263237A1 (en)2018-11-22
MY191030A (en)2022-05-29
CR20180532A (en)2019-03-04
KR20230169417A (en)2023-12-15
IL318871A (en)2025-04-01
JP2022061984A (en)2022-04-19
IL262652B2 (en)2023-10-01

Similar Documents

PublicationPublication DateTitle
SG11201809700YA (en)Gdf15 fusion proteins and uses thereof
SG11201906297QA (en)Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201809344QA (en)Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11202000312UA (en)Encapsulated polynucleotides and methods of use
SG11201907056XA (en)Compositions and methods for the treatment of hemoglobinopathies
SG11201806863WA (en)Tetracyclic pyridone compounds as antivirals
SG11201811232XA (en)Treatment of amd using aav2 variant with aflibercept
SG11201804294WA (en)Tank-binding kinase inhibitor compounds
SG11201908330PA (en)Farnesoid x receptor agonists and uses thereof
SG11201807912SA (en)Vaccine against rsv
SG11201907889YA (en)Glycan-interacting compounds and methods of use
SG11201808709VA (en)T cell receptors
SG11201808592PA (en)Method for selection of high m6p recombinant proteins
SG11201901206SA (en)Trimer stabilizing hiv envelope protein mutations
SG11201804704PA (en)Compositions and methods for decreasing tau expression
SG11201407866XA (en)Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector
SG11201809374VA (en)Cd40l-fc fusion polypeptides and methods of use thereof
SG11201804070XA (en)Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
SG11201906163TA (en)Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
SG11201900845YA (en)Uses of il-13 antagonists for treating atopic dermatitis
SG11201803975SA (en)Improved tnf binders
SG11201908512YA (en)Somatostatin modulators and uses thereof
SG11201806542PA (en)Anti-mica antibodies
SG11201908326YA (en)Methods of treating neurodegenerative diseases
SG11201903167QA (en)Compounds and methods for reducing atxn3 expression

[8]ページ先頭

©2009-2025 Movatter.jp